Erowid
 
 
Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
Get an Erowid "Words" T-shirt
Contribute $45 and show support for accurate drug information!

LSD Material Safety Data Sheet

HTML and Layout © Erowid

*--*  11-15-93  -  11:47:14  *--*
1                                                  OHS13028     PAGE 001 OF 006
                           MATERIAL SAFETY DATA SHEET
 ------------------------------------------------------------------------------
 OCCUPATIONAL HEALTH SERVICES, INC.            FOR EMERGENCY SOURCE INFORMATION
 11 WEST 42ND STREET, 12TH FLOOR               CONTACT: 1-615-366-2000
 NEW YORK, NEW YORK 10036
 1-800-445-MSDS  (1-800-445-6737) OR
 1-212-789-3535
 ------------------------------------------------------------------------------
                            SUBSTANCE IDENTIFICATION
                                                    CAS NUMBER: 50-37-3
                                                    RTECS NUMBER: KE4100000
 SUBSTANCE: LYSERGIC ACID DIETHYLAMIDE
 TRADE NAMES/SYNONYMS:
   ERGOLINE-8-CARBOXAMIDE, 9,10-DIDEHYDRO-N,N-DIETHYL-6-METHYL-, (8BETA)-;
   9,10-DIDEHYDRO-N,N-DIETHYL-6-METHYLERGOLINE-8-CARBOXAMIDE;
   ERGOLINE-8(BETA)-CARBOXAMIDE, 9,10-DIDEHYDRO-N,N-DIETHYL-6-METHYL-;
   9,10-DIDEHYDRO-N,N-DIETHYL-6-METHYLERGOLINE-8(BETA)-CARBOXAMIDE; DELYSID;
   N,N-DIETHYLLYSERGAMIDE; D-LSD; LSD-25; LSD; LSD (ALKALOID); (+)-LSD;
   D-LYSERGIC ACID DIETHYLAMIDE; LYSERGIDE; ACID; BLOTTER ACID; WINDOW PANES;
   25; BLUE DOTS; THE BEAST; C20H25N3O; OHS13028
 CHEMICAL FAMILY:
 ALKALOID
 MOLECULAR FORMULA: C20-H25-N3-O
 MOLECULAR WEIGHT: 323.48
 CERCLA RATINGS (SCALE 0-3):  HEALTH=3  FIRE=1  REACTIVITY=0  PERSISTENCE=3
 NFPA RATINGS (SCALE 0-4):  HEALTH=3  FIRE=1  REACTIVITY=0
 ------------------------------------------------------------------------------
                           COMPONENTS AND CONTAMINANTS
 COMPONENT: LYSERGIC ACID DIETHYLAMIDE                      PERCENT: 100
            CAS# 50-37-3
 OTHER CONTAMINANTS: NONE
 EXPOSURE LIMITS:
   NO OCCUPATIONAL EXPOSURE LIMITS ESTABLISHED BY OSHA, ACGIH, OR NIOSH.
 ------------------------------------------------------------------------------
                                  PHYSICAL DATA
 DESCRIPTION: TASTELESS, COLORLESS AND ODORLESS CRYSTALLINE SOLID.
 MELTING POINT: 176-185 F (80-85 C)    SPECIFIC GRAVITY: NOT AVAILABLE
 SOLUBILITY IN WATER: SOLUBLE
 SOLVENT SOLUBILITY: SOLUBLE IN BENZENE.
1                                                  OHS13028     PAGE 002 OF 006
 ------------------------------------------------------------------------------
                             FIRE AND EXPLOSION DATA
 FIRE AND EXPLOSION HAZARD:
 SLIGHT FIRE HAZARD WHEN EXPOSED TO HEAT OR FLAME.
 FIREFIGHTING MEDIA:
 DRY CHEMICAL, CARBON DIOXIDE, WATER SPRAY OR REGULAR FOAM
 (1990 EMERGENCY RESPONSE GUIDEBOOK, DOT P 5800.5).
 FOR LARGER FIRES, USE WATER SPRAY, FOG OR REGULAR FOAM
 (1990 EMERGENCY RESPONSE GUIDEBOOK, DOT P 5800.5).
 FIREFIGHTING:
 MOVE CONTAINER FROM FIRE AREA IF YOU CAN DO IT WITHOUT RISK (1990 EMERGENCY
 RESPONSE GUIDEBOOK, DOT P 5800.5, GUIDE PAGE 53).
 EXTINGUISH USING AGENT SUITABLE FOR TYPE OF SURROUNDING FIRE. AVOID BREATHING
 VAPORS AND DUSTS. KEEP UPWIND.
 ------------------------------------------------------------------------------
                                    TOXICITY
 LYSERGIC ACID DIETHYLAMIDE:
 700 NG/KG ORAL-HUMAN TDLO; 2857 NG/KG ORAL-HUMAN TDLO; 857 NG/KG ORAL-HUMAN
 TDLO; 750 NG/KG INTRAMUSCULAR-HUMAN TDLO; 16 MG/KG INTRAVENOUS-RAT LD50;
 50 MG/KG INTRAPERITONEAL-MOUSE LD50; 46 MG/KG INTRAVENOUS-MOUSE LD50; 300
 UG/KG INTRAVENOUS-RABBIT LD50; 16 MG/KG SUBCUTANEOUS-GUINEA PIG LD50;
 1800 UG/KG ORAL-WILD BIRD LD50; MUTAGENIC EFFECTS DATA (RTECS); REPRODUCTIVE
 EFFECTS DATA (RTECS).
 CARCINOGEN STATUS: NONE.
 LYSERGIC ACID DIETHYLAMIDE IS TOXIC PARENTERALLY. POISONING DUE TO
 PSYCHOTOMIMETIC AGENTS MAY AFFECT THE CENTRAL NERVOUS SYSTEM. PERSONS WITH
 EMOTIONAL DISTURBANCES OR ORGANIC BRAIN DISEASE MAY BE AT INCREASED RISK
 FROM EXPOSURE. CROSS TOLERENCE BETWEEN DIFFERENT PSYCHOTOMIMETIC AGENTS MAY
 OCCUR. INTERACTIONS WITH MEDICATIONS HAVE BEEN REPORTED.
 ------------------------------------------------------------------------------
                          HEALTH EFFECTS AND FIRST AID
 INHALATION:
 LYSERGIC ACID DIETHYLAMIDE:
   ACUTE EXPOSURE- INHALATION MAY CAUSE SYSTEMIC POISONING AS DETAILED IN
     ACUTE INGESTION.
   CHRONIC EXPOSURE- REPEATED EXPOSURE MAY CAUSE SYSTEMIC POISONING AS DETAILED
     IN CHRONIC INGESTION.
 FIRST AID- REMOVE FROM EXPOSURE AREA TO FRESH AIR IMMEDIATELY. IF BREATHING
   HAS STOPPED, PERFORM ARTIFICIAL RESPIRATION. KEEP PERSON WARM AND AT REST.
   TREAT SYMPTOMATICALLY AND SUPPORTIVELY. GET MEDICAL ATTENTION IMMEDIATELY.
 SKIN CONTACT:
 LYSERGIC ACID DIETHYLAMIDE:
   ACUTE EXPOSURE- NO DATA AVAILABLE.
   CHRONIC EXPOSURE- NO DATA AVAILABLE.
1                                                  OHS13028     PAGE 003 OF 006
 FIRST AID- REMOVE CONTAMINATED CLOTHING AND SHOES IMMEDIATELY. WASH AFFECTED
   AREA WITH SOAP OR MILD DETERGENT AND LARGE AMOUNTS OF WATER UNTIL NO
   EVIDENCE OF CHEMICAL REMAINS (APPROXIMATELY 15-20 MINUTES). GET MEDICAL
   ATTENTION IMMEDIATELY.
 EYE CONTACT:
 LYSERGIC ACID DIETHYLAMIDE:
   ACUTE EXPOSURE- SYSTEMICALLY ADMINISTERED PSYCHOTOMIMETICS MAY CAUSE
     MYDRIASIS. LYSERGIC ACID DIETHYLAMIDE MAY PRODUCE WEAKNESS OF
     ACCOMMODATION IN HUMANS AND PSYCHIC BLINDNESS IN ANIMALS. A SINGLE
     RESEARCH REPORT DESCRIBES SPONTANEOUS ACTION POTENTIALS WHICH APPEAR
     TO ORIGINATE IN THE RETINA AND ARE DETECTABLE FROM THE EYE, THE
     OPTIC NERVE AND THE OCCIPITAL VISUAL CORTEX IN SEVERELY POISONED
     CATS. NO OCULAR OR PERMANENT ALTERATION OF VISION HAS BEEN REPORTED.
     A TERATOGENIC EFFECT OF LYSERGIDE ON THE LENS HAS BEEN SHOWN TO
     RESULT FROM ADMINISTRATION OF LARGE DOSES TO PREGNANT MICE, CAUSING
     HISTOLOGICALLY OBSERVABLE ABNORMALITIES IN THE LENS EPITHELIUM
     SIMILAR TO EFFECTS PRODUCED BY X-IRRADIATION.
   CHRONIC EXPOSURE- NO DATA AVAILABLE.
 FIRST AID- WASH EYES IMMEDIATELY WITH LARGE AMOUNTS OF WATER OR NORMAL SALINE,
   OCCASIONALLY LIFTING UPPER AND LOWER LIDS, UNTIL NO EVIDENCE OF CHEMICAL
   REMAINS (APPROXIMATELY 15-20 MINUTES). GET MEDICAL ATTENTION IMMEDIATELY.
 INGESTION:
 LYSERGIC ACID DIETHYLAMIDE:
   ACUTE EXPOSURE- INGESTION OF PSYCHOTOMIMETIC AGENTS MAY CAUSE NAUSEA,
     VOMITING, OCCASIONAL DIARRHEA, SWEATING, HEADACHE, HYPERTENSION,
     TACHYCARDIA, TWITCHING, HYPERREFLEXIA, TREMORS AND INCOORDINATION.
     BILATERALLY DILATED AND REACTIVE PUPILS, NYSTAGMUS, AND PHOTOPHOBIA MAY
     OCCUR. VASODILATION, HYPOTENSION AND RESPIRATORY DEPRESSION MAY OCCUR
     AT DOSES OF 20-60 MG/KG. BRADYCARDIA MAY BE PRESENT AT HIGHER DOSES.
     CONVULSIONS AND COMA HAVE BEEN REPORTED. EFFECTS ON THE CENTRAL NERVOUS
     SYSTEM MAY INCLUDE EUPHORIA, HYPEREXCITABILITY AND ALERTNESS, RAMBLING
     SPEECH, DELIRIA, UNCONTROLLABILITY, TRANSCENDENTAL MOOD, DISTRACTABILITY,
     DEPERSONALIZATION AND IMPAIRMENT OF JUDGEMENT. A TEMPORARY PSYCHOTIC
     STATE WITH SENSORY ILLUSIONS, DISTORTIONS OR VISUAL HALLUCINATIONS
     CONSISTING OF SHIMMERING INTENSIFICATION OF COLOR AND TEXTURE,
     BRIGHTLY COLORED LIGHTS, GEOMETRIC DESIGNS, ANIMALS AND OCCASIONALLY
     HUMAN IMAGES MAY OCCUR. HEARING OR TASTING COLORS AND SEEING SOUNDS HAVE
     BEEN REPORTED. RARELY, ANXIETY, FEARFUL AUDITORY, VISUAL AND TACTILE
     HALLUCINATIONS, PANIC STATES AND PARANOID DELUSIONS, SUSPICIOUSNESS,
     EMOTIONAL LABILITY, INTENSE DEPRESSION, LOSS OF CONTROL, SUICIDAL
     IDEATION AND SELF DESTRUCTIVE OR AGGRESSIVE ACTS MAY OCCUR. DEATHS
     HAVE RESULTED FROM HALLUCINATORY EFFECTS LEADING TO ACCIDENTAL
     DEATH. ADDITIONAL EFFECTS DUE TO LYSERGIC ACID DIETHYLAMIDE MAY INCLUDE
     SALIVATION, LACRIMATION, HYPERPYREXIA, HYPERTENSION, PILOERECTION, SPASTIC
     PARESIS, HYPERACUSIS, SUGGESTIBILITY, PROLONGED PSYCHOSIS, RARELY,
     HYPERGLYCEMIA AND INTERNAL CAROTID ARTERIOSPASM WITH RESULTANT CEREBRAL
     ANOXIA AND SEIZURES. INFLAMMATORY FIBROSIS HAS BEEN REPORTED. STUDIES
     INDICATE THAT DEATH IN ANIMALS IS DUE TO RESPIRATORY FAILURE OR
     HYPERTHERMIA. IN THE HUMAN ADULT, LYSERGIC ACID DIETHYLAMIDE HAS
     BEEN ASSOCIATED WITH BREAKS AND OTHER STRUCTURAL ABNORMALITIES OF
     CHROMOSOMES. A SINGLE STUDY OF PREGNANCIES OCCURRING AFTER MEDICALLY
     ADMINISTERED DOSES DID NOT SHOW AN INCREASE IN THE RATE OF SPONTANEOUS
     ABORTIONS, PREMATURE BIRTHS, OR CONGENITAL DEFECTS OVER THE NORM.
     HOWEVER, BIRTH OF ABNORMAL BABIES HAS FOLLOWED CONSUMPTION OF ILLICIT
     LSD BY THE MOTHER IN EARLY PREGNANCY.
1                                                  OHS13028     PAGE 004 OF 006
   CHRONIC EXPOSURE- REPEATED EXPOSURE MAY CAUSE EFFECTS AS DETAILED IN
     ACUTE INGESTION. FLASHBACKS WITH HALLUCINATIONS AND DISTORTION OF
     PERCEPTION OF TIME, SPACE AND SELF IMAGE MAY OCCUR WEEKS OR MONTHS
     AFTER THE LAST DOSE. TOLERENCE AND PSYCHOLOGIC DEPENDENCE MAY OCCUR.
     FETAL LOSS HAS BEEN PRODUCED IN RATS FOLLOWING ORAL ADMINISTRATION
     OF 20 MICROGRAMS OF LYSERGIC ACID DIETHYLAMIDE BETWEEN THE FIRST AND
     FOURTH DAY OF GESTATION. NO SPECIFIC CONGENITAL DEFECTS WERE REPORTED.
 FIRST AID- TREAT SYMPTOMATICALLY AND SUPPORTIVELY. GET MEDICAL ATTENTION
   IMMEDIATELY. IF VOMITING OCCURS, KEEP HEAD LOWER THAN HIPS TO PREVENT
   ASPIRATION.
 ANTIDOTE:
 NO SPECIFIC ANTIDOTE. TREAT SYMPTOMATICALLY AND SUPPORTIVELY.
 ------------------------------------------------------------------------------
                                   REACTIVITY
 REACTIVITY:
 STABLE UNDER NORMAL TEMPERATURES AND PRESSURES.
 INCOMPATIBILITIES:
 LYSERGIC ACID DIETHYLAMIDE:
   NO DATA AVAILABLE.
 DECOMPOSITION:
 THERMAL DECOMPOSITION PRODUCTS MAY INCLUDE TOXIC OXIDES OF CARBON AND
 NITROGEN.
 POLYMERIZATION:
 HAZARDOUS POLYMERIZATION HAS NOT BEEN REPORTED TO OCCUR UNDER NORMAL
 TEMPERATURES AND PRESSURES.
 ------------------------------------------------------------------------------
                              STORAGE AND DISPOSAL
 OBSERVE ALL FEDERAL, STATE AND LOCAL REGULATIONS WHEN STORING OR DISPOSING
 OF THIS SUBSTANCE. FOR ASSISTANCE, CONTACT THE DISTRICT DIRECTOR OF THE
 ENVIRONMENTAL PROTECTION AGENCY.
                                  **STORAGE**
 STORAGE OF CONTROLLED SUBSTANCES MUST COMPLY WITH APPLICABLE SECURITY
 REQUIRMENTS IN 21 CFR 1301.71, 1301.72, 1301.73, 1301.74, 1301.75 AND 1301.76.
 ------------------------------------------------------------------------------
                              CONDITIONS TO AVOID
 MAY BURN BUT DOES NOT IGNITE READILY. PREVENT DISPERSION OF DUST IN AIR. DO
 NOT ALLOW SPILLED MATERIAL TO CONTAMINATE WATER SOURCES.
 ------------------------------------------------------------------------------
                            SPILL AND LEAK PROCEDURES
 OCCUPATIONAL SPILL:
 DO NOT TOUCH SPILLED MATERIAL. STOP LEAK IF YOU CAN DO IT WITHOUT RISK. FOR
 SMALL SPILLS, TAKE UP WITH SAND OR OTHER ABSORBENT MATERIAL AND PLACE INTO
1                                                  OHS13028     PAGE 005 OF 006
 CONTAINERS FOR LATER DISPOSAL. FOR SMALL DRY SPILLS, WITH A CLEAN SHOVEL
 PLACE MATERIAL INTO CLEAN, DRY CONTAINER AND COVER. MOVE CONTAINERS FROM
 SPILL AREA. FOR LARGER SPILLS, DIKE FAR AHEAD OF SPILL FOR LATER DISPOSAL.
 KEEP UNNECESSARY PEOPLE AWAY. ISOLATE HAZARD AREA AND DENY ENTRY.
 ------------------------------------------------------------------------------
                              PROTECTIVE EQUIPMENT
 VENTILATION:
 PROVIDE LOCAL EXHAUST OR PROCESS ENCLOSURE VENTILATION SYSTEM.
 RESPIRATOR:
 THE FOLLOWING RESPIRATORS ARE RECOMMENDED BASED ON INFORMATION FOUND IN THE
   PHYSICAL DATA, TOXICITY AND HEALTH EFFECTS SECTIONS. THEY ARE RANKED IN
   ORDER FROM MINIMUM TO MAXIMUM RESPIRATORY PROTECTION.
 THE SPECIFIC RESPIRATOR SELECTED MUST BE BASED ON CONTAMINATION LEVELS FOUND
   IN THE WORK PLACE, MUST BE BASED ON THE SPECIFIC OPERATION, MUST NOT EXCEED
   THE WORKING LIMITS OF THE RESPIRATOR AND MUST BE JOINTLY APPROVED BY THE
   NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH AND THE MINE SAFETY
   AND HEALTH ADMINISTRATION (NIOSH-MSHA).
   ANY DUST AND MIST RESPIRATOR WITH A FULL FACEPIECE.
   ANY AIR-PURIFYING FULL FACEPIECE RESPIRATOR WITH A HIGH-EFFICIENCY
     PARTICULATE FILTER.
   ANY POWERED AIR-PURIFYING RESPIRATOR WITH A TIGHT-FITTING FACEPIECE AND
     HIGH-EFFICIENCY PARTICULATE FILTER.
   ANY TYPE 'C' SUPPLIED-AIR RESPIRATOR WITH A FULL FACEPIECE OPERATED IN
     PRESSURE-DEMAND OR OTHER POSITIVE PRESSURE MODE OR WITH A FULL FACEPIECE,
     HELMET OR HOOD OPERATED IN CONTINUOUS-FLOW MODE.
   ANY SELF-CONTAINED BREATHING APPARATUS WITH A FULL FACEPIECE OPERATED IN
     PRESSURE-DEMAND OR OTHER POSITIVE PRESSURE MODE.
 FOR FIREFIGHTING AND OTHER IMMEDIATELY DANGEROUS TO LIFE OR HEALTH CONDITIONS:
   ANY SELF-CONTAINED BREATHING APPARATUS THAT HAS A FULL FACEPIECE AND IS
     OPERATED IN A PRESSURE-DEMAND OR OTHER POSITIVE-PRESSURE MODE.
   ANY SUPPLIED-AIR RESPIRATOR THAT HAS A FULL FACEPIECE AND IS OPERATED IN A
     PRESSURE-DEMAND OR OTHER POSITIVE-PRESSURE MODE IN COMBINATION WITH AN
     AUXILIARY SELF-CONTAINED BREATHING APPARATUS OPERATED IN PRESSURE-DEMAND
     OR OTHER POSITIVE-PRESSURE MODE.
 CLOTHING:
 EMPLOYEE MUST WEAR APPROPRIATE PROTECTIVE (IMPERVIOUS) CLOTHING AND EQUIPMENT
 TO PREVENT REPEATED OR PROLONGED SKIN CONTACT WITH THIS SUBSTANCE.
 GLOVES:
 EMPLOYEE MUST WEAR APPROPRIATE PROTECTIVE GLOVES TO PREVENT CONTACT WITH THIS
 SUBSTANCE.
 EYE PROTECTION:
 EMPLOYEE MUST WEAR SPLASH-PROOF OR DUST-RESISTANT SAFETY GOGGLES TO PREVENT
1                                                  OHS13028     PAGE 006 OF 006
 EYE CONTACT WITH THIS SUBSTANCE.
 EMERGENCY EYE WASH: WHERE THERE IS ANY POSSIBILITY THAT AN EMPLOYEE'S EYES MAY
 BE EXPOSED TO THIS SUBSTANCE, THE EMPLOYER SHOULD PROVIDE AN EYE WASH
 FOUNTAIN WITHIN THE IMMEDIATE WORK AREA FOR EMERGENCY USE.
 ------------------------------------------------------------------------------
   COPYRIGHT  1992  OCCUPATIONAL HEALTH SERVICES, INC..  ALL RIGHTS RESERVED.
           CREATION DATE: 07/29/88          REVISION DATE: 10/12/92